Fig 3.

Expression levels of CD203c on basophils measured by flow cytometric analysis. (a) Original response levels in hypersensitivity reaction (HR)(+) and HR(−) patients, of the selected healthy subject for monoclonal and polyclonal anti-IgE antibodies, and for carboplatin (CBDCA). The HR(+) patient data are from those whose responses to CBDCA were highest among the CBDCA patients. (b) Response levels of healthy subject's basophils after passive sensitization with HR(+) patients' plasma with or without omalizumab treatment, or with HR(−) patients' plasma. In (a) and (b), flow cytometer charts for CD3⁻ PBMCs are shown. Upregulation of CD203c on basophils was determined using a threshold that was defined as the expression level above which 2% of basophils in the negative control column fluoresce, on average. Mean fluorescence intensities (MFIs) indicated for binding levels of CD203c on basophils. (c) Correlation of response levels to CBDCA of sensitized basophils and of corresponding IgE donor patients' original basophils (n = 5). ΔMFI was calculated as the difference between the negative control and CBDCA-stimulated sample, with respect to the MFI of PE-labeled CD203c.